Therapeutic | Porustobart |
Target | CTLA4 |
Heavy Chain | EVQLVESGGGLIQPGGSLRLSCAVSGFTVSKNYMSWVRQAPGKGLEWVSVVYSGGSKTYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPHSPSSFDIWGQGTMVTVSS |
Light Chain | na |
100% seqID Fv Structure | 7dv4 [Fvs: B, D, F, H] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 7dv4 [Fvs: B, D, F, H] |
Follow these links to our prediction tools:
Format | VH-CH2-CH3 |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-II |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2022 |
INN Year Recommended | None |
Companies Involved | Harbour Biomed |
Conditions Approved | na |
Conditions Active | Solid tumours |
Conditions Discontinued | na |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]